Severe COVID-19 Associated With Liver Injury in Patients Without Preexisting Liver DiseaseFamily/General Practice Published on 2021-04-262022-10-31 Journal: Cureus [Category] COVID-19, [키워드] Alanine albumin alkaline phosphatase ALT appear assessment AST ast (aspartate aminotransferase) Bilirubin chronic liver disease Coronavirus disease 2019 cough COVID-19 diabete Dyspnea elevated Evidence failure ferritin Inflammatory response Leukocytosis limit liver Liver disease Liver function test liver function tests Liver injury male Mild moderate disease Mortality Patient patients procalcitonin raised severity of COVID-19 Severity of disease single-center SIRS SOFA syndrome systemic inflammatory response tachypnea were assessed were excluded with COVID-19 [DOI] 10.7759/cureus.14705 PMC 바로가기 [Article Type] Family/General Practice
Prevalence, clinical features, and outcomes of SARS-CoV-2 infection in pregnant women with or without mild/moderate symptoms: Results from universal screening in a tertiary care center in Mexico City, Mexico경증/중등도 증상이 있거나 없는 임산부에서 SARS-CoV-2 감염의 유병률, 임상 양상 및 결과: 멕시코 멕시코시티에 있는 3차 의료 센터의 보편적 선별 검사 결과Research Article Published on 2021-04-222022-09-10 Journal: PLoS ONE [Category] MERS, SARS, 치료기술, [키워드] 95% CI Admission age Asymptomatic baseline Birth Body body mass body mass index both group both groups Care case-control study Clinical features community transmission complications condition consequence COVID-19 COVID-19 test death discharged Diseases feature gestational age highest highlight Hospitalization Illness severity index Infant mass maternal age Maternal death median Mexico City mild symptoms moderate disease mother Neonate Neonates NICU nine no differences number of infected Obstetric outcome outcomes Patient percentage positive preeclampsia Pregnancy pregnant women prevalence of COVID-19 proportion Quantitative Quantitative RT-PCR reported Result retrospective risk factor Risk factors RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 test severe COVID-19 Severity of infection test result the patient Transmission women [DOI] 10.1371/journal.pone.0249584 PMC 바로가기 [Article Type] Research Article
COVID-19 Severity and Neonatal BCG Vaccination among Young Population in TaiwanCommunication Published on 2021-04-182022-10-30 Journal: International Journal of Environmental Research an [Category] COVID-19, MERS, SARS, [키워드] acute respiratory distress age Asymptomatic Bacillus Calmette–Guérin BCG BCG vaccination center Control Coronavirus disease 2019 COVID-19 COVID-19 severity Critical disease defined described died disease examined immunization indicated individual Mild mild illness moderate disease Neonatal occurred participant Patient Population reported SARS-CoV-2 severe disease severity syndrome System Taiwan vaccinated individuals vaccination World Health Organization [DOI] 10.3390/ijerph18084303 PMC 바로가기 [Article Type] Communication
Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 CoronavirusSARS-CoV-2 코로나바이러스에 대한 항체 반응에 대한 치료 요법의 영향Immunology Published on 2021-04-152022-09-12 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, [키워드] 95% CI absence affecting age analyzed Antibody Response Antibody test antimalarial drug asymptomatic patients Cancer cephalosporins chloroquine/hydroxychloroquine Clinical characteristics convalescent stage coronavirus disease correlated COVID-19 Critical Critically ill patient determine develop Dyspnea Evidence Factor Fever global pandemic IgG IgG antibody IgG response IgM/IgG Impact Limited Mild Moderate COVID-19 moderate disease Mortality mortality rate multivariable analysis negativity onset of symptoms Patient Predictive Prognosis progressed progression reported response risk factor SARS-CoV-2 SARS-CoV-2 antibody Seroconversion Spread Symptom the patient the SARS-CoV-2 treatment regimen univariable analysis was determined was performed Wuhan [DOI] 10.3389/fimmu.2021.580147 PMC 바로가기 [Article Type] Immunology
RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trialResearch article Published on 2021-04-142022-10-05 Journal: EClinicalMedicine [Category] 임상, [키워드] 95% CI adaptive Adverse age anaphylaxis antibodies antibody assigned baseline blinded category Clinical improvement clinical scale clinical trial conducted dose double-blind Efficacy and safety Endpoint enrolled equine event finding Follow-up hazard ratio hospital hospital discharge Hospitalized hospitalized patient Immunotherapy interquartile range male Mild moderate disease Mortality multicenter neutralizing antibody Patient patients with COVID-19 patients with moderate phase 2/3 Placebo placebo-controlled placebo-controlled trial polyclonal polyclonal antibody primary endpoint Randomized Rate reached receive reported risk SARS-CoV-2 SARS-CoV-2 pneumonia severe COVID-19 Severe COVID-19 pneumonia severe disease Severe patient significantly higher statistically statistically significant difference study group subgroup analysis symptoms onset the placebo group the primary endpoint therapeutic time Treatment WHO [DOI] 10.1016/j.eclinm.2021.100843 [Article Type] Research article
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study입원하지 않은 경증에서 중등도의 COVID-19 환자에서 장내 미생물군유전체 조절의 자연사 및 영향을 평가하기 위한 가상화된 임상 연구 장내 미생물군 구조에 대한 KB109의 생리학적 효과를 평가하는 병렬 그룹 연구와 함께 무작위, 공개, 전향적 연구 및 기능: 무작위 대조 연구를 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-04-022022-09-10 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 1:1 24 hours Ability absence addition adhere Affect age Ageusia allergy analysed Anosmia Anosmia/ageusia Antacid Antibiotics Antiviral assessment assigned Autoimmune disease Bariatric surgery baseline bilevel positive airway pressure Biomarker Biomarkers biomarkers of inflammation BiPAP Blinding blocker Blood blood sample Blood samples both groups bowel bowel resection breath Care care provider Cell change Chest chest tightness chills chronic lung disease cirrhosis clinical clinical study clinical trial Cold collected Community Comorbidity comparator Patients completion Compliance component computer Concomitant medication concomitant medications concurrent condition conducted contraindications coronavirus disease Coronavirus disease 2019 cough COVID-19 COVID-19 in patient COVID-19 symptom COVID-19 symptoms COVID-19 testing COVID-19-related symptom COVID-19-related symptoms COVID-19–related symptom COVID-19–related symptoms CPAP Cytokines D-dimer daily dose Day defined diarrhea dissemination drug duration of symptom Effect element eligible Enrollment evaluate evaluate the effect evaluated exacerbated exclusion criteria exploratory fatigue fatty Fatty acid feasible Female patients Fever fiber Follow-up follow-up period following group Gut gut microbiome gut microbiome composition gut microbiota headache Health Health care Health Care Utilization Health status healthcare Histamine history hospital Hospital admission Hospital admissions Hospitalization Hospitalized hypoxia Identifier IgM/IgG Immunity immunomodulatory immunosuppressive immunosuppressive therapy in both group include Infection Inflammation Inflammatory biomarker Inflammatory bowel disease information Informed consent inhibitors intake Interaction investigational agent irritable bowel syndrome KB109 Laboratory laboratory measures lactating library life Liver disease Lung disease magnitude malignancy management measure Measures medication medications Medicine metabolite Microbiome microbiota Mild mild to moderate Mild to moderate COVID-19 mild to moderate disease moderate Moderate COVID-19 moderate disease modulate modulation muscle pain nasal congestion neutralization assays not limited nucleic acid number objective Open-label opinion other compound other compounds outcome outcome measure Outpatient outpatients oxygen oxygen saturation Oxygen therapy Pain parallel group participant Participation Patient patient population Period Physical examination positive airway pressure Positive test Potential pre-symptomatic pregnant Primary outcome progression proportion proportions Prospective Study PROTECT protocol protocols proton pump provided pulse Pulse oximeter Quality of life Quantitative question randomisation randomised randomised controlled study randomization Randomized randomized controlled study receive recruitment reduction Registered reported response resting position risk risk of infection Sample size screened selected self-care sensitivities Sequencing serological serology shaking short-chain fatty acids Shortness of breath Sleep sleep apnea Smartphone sore throat specific biomarker specific biomarkers Spread SSC Standard Stool stratified Study design Study protocol study visit supplementary material Swab Symptom symptomatic patient Symptomatic patients Symptoms syndrome Tablet TEAEs Telemedicine telephone temperature the patient The United States therapy time Tolerability Treatment treatment-emergent adverse event undergo United States unlikely Viral Viral load water website worsening [DOI] 10.1186/s13063-021-05157-0 PMC 바로가기 [Article Type] Letter
Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?COVID-19에서 하이드록시클로로퀸 예방에 대한 통제된 임상 시험에서 위약으로서의 엽산: 과학적으로 정당화될 수 있습니까?Article Published on 2021-04-012022-08-31 Journal: Medical Hypotheses [Category] MERS, 임상, 치료제, [키워드] ACE2 benefit Clinical studies Combination complicate Controlled clinical trial COVID-19 cyanocobalamin disease severity domains Efficacy Factor failure Folic acid furin Hydroxychloroquine hypertension Hypothesis Interpretation Laboratory lowest Mild moderate disease MTHFR Other parameters Placebo placebo controlled trial polymorphism Prevalence Prophylaxis protease pulmonary hypertension Pyridoxine RCT reported SARS-CoV-2 Severe patient severe patients Trial Variation [DOI] 10.1016/j.mehy.2021.110539 PMC 바로가기 [Article Type] Article
Evaluation of SARS-CoV-2 in Tears of Patients with Moderate to Severe COVID-19중등도에서 중증 COVID-19 환자의 눈물에서 SARS-CoV-2 평가Article Published on 2021-04-012022-09-11 Journal: Ophthalmology [Category] SARS, 치료기술, [키워드] 48 hour 48 hours amplification curve Analysis Chain Reaction collected Comorbidities conjunctival Conjunctival swab coronavirus disease Coronavirus disease 2019 COVID-19 cross-sectional study Ct value Ct values cycle threshold E gene enrolled eye Frame gold gold standard group laboratory confirmation manifestation median value moderate moderate disease moderate to severe nasopharyngeal Nasopharyngeal swab ocular Open reading frame outcome Patient patients patients with moderate polymerase chain polymerase chain reaction positive positive result positive RT-PCR profiles real-time RT-PCR reverse-transcriptase polymerase chain reaction RNA-dependent RNA polymerase RT-PCR analysis RT-PCR assay Sample SARS-CoV-2 SARS-CoV-2 RNA severe coronavirus disease severe COVID-19 severe disease significantly higher specimen statistically significant Swab Symptomatology systemic symptoms Tear tears threshold transported Viral load Viral transmission viral transport media was determined [DOI] 10.1016/j.ophtha.2020.08.029 PMC 바로가기 [Article Type] Article
Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)COVID-19의 덜 심각한 과정은 계절성 인간 코로나바이러스 OC43 및 HKU1(HCoV OC43, HCoV HKU1)에 대한 항체 수치 상승과 관련이 있습니다.Article Published on 2021-04-012022-09-11 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 바이오마커, 진단, [키워드] age antibody Biomarker Clinical course Confirmed COVID-19 infection Coronaviruses Course COVID-19 COVID-19 infections COVID-19 patients COVID-19 severity Critical disease disease elevated HCoV HKU1 human coronavirus infected individual Infection Inpatient intensive care levels of antibody males moderate disease OC43 outpatients Patient performed proportion PROTECT resulting seasonal seasonal coronavirus seasonal coronaviruses significantly lower [DOI] 10.1016/j.ijid.2021.02.085 PMC 바로가기 [Article Type] Article
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory diseaseArticle Published on 2021-03-192022-10-30 Journal: NPJ Vaccines [Category] COVID-19, [키워드] Ad26 Ad26.COV2.S added addition benefit binding Breakthrough infection condition dose Efficacy elicited ENhance exacerbate expressing hamster immune response Immunity immunogenic immunology Infection inoculated investigated low-dose Lower respiratory tract Lung infection moderate disease neutralizing antibodies titer Neutralizing antibody titer non-human primate Pneumonia preclinical data prefusion prevalent Probability PROTECT Protective provide recombinant adenovirus regimen Respiratory disease SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike antigen SARS-CoV-2 variant SARS-CoV-2 virus serotype shown single dose the vaccine upper respiratory tract vaccination Vaccine vaccine dose Vaccines variant Viral load [DOI] 10.1038/s41541-021-00301-y PMC 바로가기 [Article Type] Article